Highlights from the Swedish Orphan Biovitrum AGM Held on May 6, 2026

Swedish Orphan Biovitrum's Annual General Meeting Overview

On May 6, 2026, the Annual General Meeting (AGM) of Swedish Orphan Biovitrum AB, commonly known as Sobi®, convened to discuss vital resolutions shaping the company's future. Shareholders gathered to review the financial statements, board elections, and strategic initiatives aimed at enhancing Sobi’s approach to rare diseases.

The AGM commenced with the adoption of the profit and loss statements, along with the balance sheet for the financial year 2025. This critical step allows Sobi to carry forward retained profits, demonstrating the company's ongoing commitment to shareholder value and operational success. In line with these developments, the board members and the CEO received a discharge of liability, signifying shareholder approval for their actions during the past fiscal year.

Board of Directors: Elections and Allocations

A substantial part of the meeting focused on the elections of the Board of Directors. Notably, Christophe Bourdon, Iris Loew-Friedrich, David Meek, Staffan Schüberg, and Filippa Stenberg were re-elected. In a significant move, Mikael Dolsten and Åsa Riisberg joined the board, ensuring a blend of experience and fresh perspectives until the next AGM. David Meek’s re-election as Chair of the Board was another highlight, reflecting the trust placed in his leadership.

Shareholders also approved the remuneration structure for both the Board of Directors and the Auditor, Ernst Young AB, which will serve until the conclusion of the following AGM.

Long-Term Incentive Programs and Share Issuance Proposals

In a robust show of faith towards employee engagement and retention, the AGM accepted proposals for long-term incentive programs. These programs encompass multiple components, including an All Employee Program designed to issue a maximum of 223,677 series C shares. Furthermore, shareholders authorized the Board to repurchase all issued series C shares and transfer up to 170,200 common shares to participants in the All Employee Program.

Additionally, the Board received authorization to issue new shares, convertible bonds, or warrants, with cumulative limits set at 39,710,000 shares. This decision aligns with Sobi’s strategic growth plans while enhancing liquidity measures within its operational framework. The AGM also approved the transfer of no more than 763,064 own common shares on the stock exchange to cover various liabilities related to previous incentive programs.

Looking Ahead: Corporate Philosophy and Commitment

These key decisions made during the AGM exemplify Sobi’s commitment to advancing its mission of delivering innovative therapies for people living with rare diseases. Currently employing around 2,000 talents across Europe, North America, the Middle East, Asia, and Australia, Sobi has showcased impressive financial performance, reporting revenues of approximately SEK 28 billion in 2025. This impressive figure underscores the company’s robust pipeline and its critical role within the biopharmaceutical industry.

As Sobi continues its journey, the company remains focused on unlocking new possibilities in biopharmaceutical innovations, steadfast in transforming the lives of those who depend on their products.

For more comprehensive insights regarding the decisions made during this AGM, visit sobi.com where full details and ongoing updates about Sobi’s initiatives are available.